4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001193125-26-022845
Chief Financial Officer sold 34,972 shares at $60.19 ($2,104,965)
- Chief Financial Officer acquired 34,972 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Prasad Raju Chief Financial Officer | 2026-01-22 | Option exercise 10b5-1 | +34,972 | $45.15 | $1,578,986 | 41,739 | D |
| Prasad Raju Chief Financial Officer | 2026-01-22 | Sale 10b5-1 | −34,972 | $60.19 | $2,104,965 | 6,767 | D |
| Derivatives | |||||||
| Prasad Raju Chief Financial Officer | 2026-01-22 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −34,972 | 41,667 | D | ||
| Open-market sales · 34,972 sh · avg $60.19 · $2,104,965 | |||||||
Loading xslF345X05/ownership.xml…